AL102

DRUG2 trials

Sponsors

Immunome Inc., Immunome, Inc.

Conditions

DesmoidDesmoid TumorProgressing desmoid tumors

Phase 2

A Study of AL102 in Patients With Progressing Desmoid Tumors

Active, not recruitingNCT04871282

Immunome, Inc.Desmoid, Desmoid Tumor

Start: 2021-09-01End: 2026-12-01Updated: 2026-06-08

RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Active, not recruitingCTIS2024-515909-26-00

Immunome Inc.Progressing desmoid tumors

Start: 2022-01-26Target: 63Updated: 2025-09-12

Related Papers

RINGSIDE: A phase 3 randomized, placebo-controlled trial of varegacestat for treatment of progressing desmoid tumors.

Journal of Clinical Oncology2026-05-27

Subgroup analysis of the phase 2 part of the RINGSIDE phase 2/3 trial of varegacestat for treatment of desmoid tumors.

Journal of Clinical Oncology2025-05-28

Change in T2-weighted signal intensity, change in tumor volume, and exposure-response analysis in the RINGSIDE phase 2 study of varegacestat in patients with desmoid tumors.

Journal of Clinical Oncology2025-05-28

RINGSIDE phase 2/3 trial of AL102 for treatment of desmoid tumors (DT): Phase 2 results.

Journal of Clinical Oncology2023-06-018 citations